Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

583
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
583
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

436
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
436
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

1.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.8K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.4K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.4K
Cancer Survival Analysis01:21

Cancer Survival Analysis

313
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
313

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extensively hydrolyzed versus intact milk protein formula and risk of necrotizing enterocolitis: a meta-analysis.

Frontiers in pediatrics·2026
Same author

Optimizing drug combinations to resurrect the potency of failed antibody therapy against emerging COVID-19 variants using IDentif.AI.

Frontiers in digital health·2026
Same author

A multicentre phase 2 study of trifluridine/tipiracil in recurrent/metastatic platinum resistant nasopharyngeal carcinomas.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Unique Digital Images as Incentives in Clinical Trials: A Digital Shift Toward Meaningful Participation.

Journal of medical Internet research·2026
Same author

Rationale and study design for a randomized clinical trial of HOPE-Genomics, a web-based intervention to improve cancer patients' understanding of genomic testing results.

Contemporary clinical trials·2026
Same author

Corrigendum to "Oculomics and AI: The eye as a biomarker for health span" [Asia-Pac J Ophthalmol 15 (1) (2026) 100282].

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026

Related Experiment Video

Updated: May 21, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.4K

AI-assisted warfarin dose optimisation with CURATE.AI for clinical impact: Retrospective data analysis.

Tiffany Rui Xuan Gan1, Lester W J Tan2,3,4, Mathias Egermark2,3,4

  • 1Division of Surgery Ng Teng Fong General Hospital Singapore Singapore.

Bioengineering & Translational Medicine
|May 19, 2025
PubMed
Summary
This summary is machine-generated.

Artificial intelligence (AI) can optimize warfarin dosing, improving accuracy and reducing risks. CURATE.AI demonstrated superior prediction error and negligible underprediction bias compared to existing models.

Keywords:
artificial intelligenceblood coagulationclinicaldecision support systemsprecision medicinewarfarin

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.7K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.2K

Related Experiment Videos

Last Updated: May 21, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.4K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.7K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.2K

Area of Science:

  • Pharmacogenomics
  • Artificial Intelligence in Medicine
  • Clinical Decision Support Systems

Background:

  • Standard warfarin dosing relies on physician guidance, often leading to suboptimal International Normalized Ratio (INR) control.
  • Inter- and intra-patient variability in warfarin response can result in adverse events like bleeding or thrombosis.

Purpose of the Study:

  • To evaluate CURATE.AI, an AI platform, for optimizing warfarin dose titration.
  • To compare the performance of CURATE.AI against existing models and physician-guided dosing.

Main Methods:

  • A personalized CURATE.AI response profile was created using patient warfarin doses and INR changes.
  • CURATE.AI's predictive performance was assessed using metrics like Percentage Absolute Prediction Error and Percentage Prediction Error.
  • Retrospective analysis of 127 patients' data.

Main Results:

  • CURATE.AI showed improved prediction accuracy (lower Percentage Absolute Prediction Error and Percentage Prediction Error of 20%) compared to other models.
  • The AI demonstrated negligible underprediction bias, potentially reducing bleeding risk.
  • Modeled time in therapeutic range with CURATE.AI was comparable to physician-guided dosing.

Conclusions:

  • CURATE.AI offers a systematic approach to warfarin dosing, reducing physician guesswork.
  • This AI platform can support effective warfarin use, potentially avoiding expensive novel anticoagulants.
  • Further prospective studies are warranted to establish CURATE.AI as a clinical decision support tool.